Organon & Co.
For the period ended Mar 31, 2024. Filed May 3, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 3, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Number | Description | ||
|---|---|---|---|
| +10.1 | — | Organon & Co. Executive Severance Program, as amended and restated on February 8, 2024 (incorporated by reference to Exhibit 10.21 to the Company's Annual Report on Form 10-K (File No. 001-40235) filed on February 26, 2024). | |
| +10.2 | — | Form of Executive Separation Agreement (incorporated by reference to Exhibit 10.38 to the Company's Annual Report on Form 10-K (File No. 001-40235) filed on February 26, 2024). | |
| *31.1 | — | Certification of Principal Executive Officer (CEO) pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| *31.2 | — | Certification of Principal Financial Officer (CFO) pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| **32.1 | — | Section 1350 Certification of Principal Executive Officer (CEO) pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| **32.2 | — | Section 1350 Certification of Principal Financial Officer (CFO) pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 101.INS | — | XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document. | |
| 101.SCH | — | XBRL Taxonomy Extension Schema Document. | |
| 101.CAL | — | XBRL Taxonomy Extension Calculation Linkbase Document. | |
| 101.DEF | — | XBRL Taxonomy Extension Definition Linkbase Document. | |
| 101.LAB | — | XBRL Taxonomy Extension Label Linkbase Document. | |
| 101.PRE | — | XBRL Taxonomy Extension Presentation Linkbase Document. | |
| 104 | — | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | |
| + · Management contract or compensatory plan or arrangement. | |||
| * · Filed herewith | |||
| ** · Furnished herewith | |||
1 Indicates, in this Form 10-Q for Quarter Ending March 31, 2024, brand names of products, which are not available in the United States.
2 Indicates, in this Form 10-Q for Quarter Ending March 31, 2024, brand names of products, which are trademarks not owned by the Company or its subsidiaries. Humirais a trademark registered in the United States in the name of AbbVie Biotechnology Ltd.; Enbrelis a trademark registered in the United States in the name of Immunex Corporation; Remicade is a trademark registered in the United States in the name of Janssen Biotech, Inc.; and Herceptin is a trademark registered in the United States in the name of Genentech, Inc.; Emgality is a trademark registered in the United States in the name of Eli Lilly and Company (used under license); and Rayvowis a registered trademark of Eli Lilly in the European Union and other countries (used under license). Brand names of products that are in all italicized letters, without the footnote, are trademarks of, or are otherwise licensed by, Organon and/or one of its subsidiaries.
-31-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.